Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2025 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
March 12, 2025 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
March 06, 2025 16:02 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
March 04, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
January 29, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
December 10, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
August 13, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
May 14, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 06, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma to present at upcoming investor conferences.
May 02, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

aTyr Pharma announces first quarter 2024 results and provides corporate update

Next Page keyboard_arrow_right